



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/081,953	02/22/2002	William J. Hennen	2820-4428.2US	6427
24247	7590	07/31/2008	EXAMINER	
TRASK BRITT			CHEN, STACY BROWN	
P.O. BOX 2550			ART UNIT	PAPER NUMBER
SALT LAKE CITY, UT 84110			1648	
NOTIFICATION DATE		DELIVERY MODE		
07/31/2008		ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTOMail@traskbritt.com

Office Action Summary	Application No. 10/081,953	Applicant(s) HENNEN ET AL.
	Examiner Stacy B. Chen	Art Unit 1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 04 June 2008.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-16 and 18-23 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-16 and 18-23 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on 22 February 2002 is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/06)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____

5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 4, 2008 has been entered. Claims 1-16 and 18-23 are pending and under examination.

Claims Summary

2. The claims are drawn to a method for inducing a T-cell mediated immune response in an animal by administering a composition comprising an extract of an egg. The extract consists essentially of water soluble proteins of an egg yolk having molecular weights of about 8 kDa or less. The phrase, "consists essentially of" in this context is interpreted as "comprising" by the Office. The specification does not appear to recite "consists essentially of" or define the term. According to the MPEP, 2111.03, "Transitional Phrases", a "consisting essentially of" claim occupies a middle ground between closed claims that are written in a "consisting of" format and fully open claims that are drafted in a "comprising" format *PPG Industries v. Guardian Industries*, 156 F.3d 1351, 1354, 48 USPQ2d 1351, 1353-54 (Fed. Cir. 1998). For the purposes of searching for and applying prior art under 35 U.S.C. 102 and 103, absent a clear indication in the specification or claims of what the basic and novel characteristics actually are, "consisting essentially of" will be construed as equivalent to "comprising." See, e.g., *PPG*, 156 F.3d at

1355, 48 USPQ2d at 1355 ("PPG could have defined the scope of the phrase consisting essentially of" for purposes of its patent by making clear in its specification what it regarded as constituting a material change in the basic and novel characteristics of the invention.").

Claim Rejections - 35 USC § 112

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

(New Rejection) Claims 1-16 and 18-23 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims now recite, "the extract consisting essentially of water soluble proteins of a yolk of an egg having molecular weights of about 8 kDa or less". The phrase "consisting essentially of" was not previously recited in the claims and does not appear to be in the specification as originally filed. It appears that Applicant is relying on the phrase to further limit the contents of the extract, however the specification as originally filed does not assign any particular meaning as to the contents of the extract in the context of "consisting essentially of". Clarification/correction is required.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(c) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-16 and 19-23 remain rejected under 35 U.S.C. 102(c) as being anticipated by Dopson (PGPub 2002/0044942A1, "Dopson", published April 18, 2002, with priority to provisional application 60/233,400, filed September 18, 2000), for reasons of record. Applicant indicates in the response filed June 4, 2008 that an affidavit may be filed once all other issues in this application are resolved.

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The rejection of claims 1, 2, 5, 7, 8, 10-13, 16 and 18-22 under 35 U.S.C. 103(a) as being unpatentable over Klesius *et al.* (*Poultry Science*, 1984, 63:1333-1337, "Klesius") in view of Rozzo *et al.* (*Molecular Immunology*, 1992, 29(2):167-182, "Rozzo") is maintained for reasons of record.

The rejection of claims 3, 4, 6, 9, 14 and 15 under 35 U.S.C. 103(a) as being unpatentable over Klesius *et al.* (*Poultry Science*, 1984, 63:1333-1337, "Klesius") in view of Rozzo *et al.* (*Molecular Immunology*, 1992, 29(2):167-182, "Rozzo"), as applied to claims 1 and 7 above, and further in view of Kirkpatrick (US Patent 5,840,700) is maintained for reasons of record.

Applicant's arguments have been carefully considered but fail to persuade. Applicant argues that neither the Klesius reference nor the Rozzo reference disclose the use of an extract consisting essentially of egg yolk proteins, including transfer factor, having molecular weights of 8 kDa or less. Applicant asserts that the composition of Klesius and Rozzo would include other proteins than transfer factor.

In response to Applicant's arguments, the Office has interpreted the phrase "consisting essentially of" as "comprising" for the reasons set forth above. With this interpretation, the composition of Klesius in view of Rozzo meets the limitations of the claims. The claims only require that the extract contain transfer factor and that the molecules in the extract be of a molecular weight of 8 kDa or less. Given the molecular weight of transfer factor (taught by Rozzo to be about 5 kDa), it would have been *prima facie* obvious for one of ordinary skill in the art to purify the transfer factor disclosed in Klesius in order to arrive at a highly purified composition of transfer factor. One would have been motivated to purify Klesius' transfer factor composition in order to, as suggested by Rozzo, study its actions more definitively (abstract). By administering highly purified transfer factor in Klesius' method, one would be able to determine more accurately the action of transfer factor as opposed to a combination of actions from interfering molecules present in the composition. Another reason one would have been

motivated to purify Klesius' transfer factor is the general practice in the art of purifying molecules of interest. Therefore, the rejections are maintained for reasons of record.

Conclusion

6. No claim is allowed.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30), alternate Fridays off. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/Stacy B. Chen/
Primary Examiner, TC1600